Previous 10 | Next 10 |
home / stock / ortif / ortif news
Ortho Regenerative Technologies Inc. (ORTIF): FY GAAP EPS of -C$0.13.Cash balance of C$2.38MSedar filingPress Release For further details see: Ortho Regenerative Technologies Inc. reports FY results
Ortho Regenerative Technologies Reports Its Fourth Quarter and 2021 Year-End Results Canada NewsWire $6.7 million raised from non-brokered private placements with insider's participation totaling $1.1 million ORTHO-R designated as a Drug/Biologic comb...
Ortho Regenerative Technologies (ORTIF) announces that it has submitted an Investigational New Drug ("IND") application to the U.S. FDA for the initiation of a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.The phase I/II clinical trial is a prospective, randomized...
Ortho Regenerative Technologies Announces Submission of Investigational New Drug Application for ORTHO-R PR Newswire Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021 MONTRÉAL, April 6, 2021 /PRNewsw...
Ortho Regenerative Technologies Secures DTC Eligibility for the Trading of Its Shares On the US OTCQB Market Canada NewsWire MONTRÉAL, March 31, 2021 /CNW/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho RTI " or the "...
Ortho Regenerative Technologies Well-positioned for Next Phase of Development PR Newswire MONTREAL , March 2, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho RTI " or the " Company "), a clinical s...
Ortho Regenerative Technologies launches AGORACOM platform for online investors outreach PR Newswire MONTREAL , Feb. 10, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc . ( CSE: ORTH) (OTCQB: ORTIF ) (" Ortho RTI " or the " Company ...
Ortho Regenerative Technologies Retains Westwicke ICR as Investor Relations Advisors for the U.S. PR Newswire MONTRÉAL, Feb. 4, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho RTI " or the " Company "), a...
Ortho Regenerative Technologies (ORTIF) has entered into a global licensing agreement with Hanuman Pelican for the use of the Buoy Suspension Fractional System in combination with Ortho-R, the company's lead Chitosan-PRP hybrid drug/biologic implant combination product.It is designed to ...
Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc. Canada NewsWire Provides Ortho RTI with worldwide rights to commercialize Buoy Suspension Fractional System in combination with Ortho-R Provides Ortho RTI with Hanuman Buo...
News, Short Squeeze, Breakout and More Instantly...
Ortho Regenerative Technologies Inc Company Name:
ORTIF Stock Symbol:
OTCMKTS Market:
Ortho Regenerative Technologies Inc Website:
(NewsDirect) ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,0...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES CORPORATE NAME CHANGE TO CHITOGENX Canada NewsWire New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL , Sept. 7, 2022 /CNW Telbec/ ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire First patient surgery completed; additional surgeries already scheduled 8 clinical centres now fully initi...